• Event Type: The document is a regulatory filing containing the full transcript of the Q1 FY27 Earnings Conference Call for Global Health Limited (Medanta).
  • Date and Time: The earnings conference call was held on Friday, July 31, 2026. The specific time and time zone were not mentioned in the provided transcript.
  • Purpose: The purpose of the call was to discuss the company's financial and operational performance for the first quarter ended June 30, 2026 (Q1 FY27).
  • Management Participants: The following management representatives participated in the call:
  • Dr. Naresh Trehan – Chairman and Managing Director
  • Mr. Pankaj Sahni – Group Chief Executive Officer and Director
  • Mr. Yogesh Kumar Gupta – Chief Financial Officer
  • Mr. Gaurav Chugh – Head Investor Relations
  • Moderator: The call was hosted and moderated by Mr. Amey Chalke from JM Financial Institutional Securities.
  • Availability of Materials: The transcript notes that the results and presentations were released the day before the call (July 30, 2026). The transcript itself is stated to be available on the company's investor relations website: https://www.medanta.org/investor-relation.
  • UPSI Statement: The transcript does not contain any explicit compliance language stating that no Unpublished Price Sensitive Information (UPSI) would be shared. The call consisted of a detailed review of published results and Q&A.

Financial and Operational Highlights from the Call

The management provided a detailed breakdown of the Q1 FY27 performance:

Consolidated Financials:

  • Total Income: INR 13,262 million (26% YoY growth)
  • EBITDA (excluding Noida): INR 3,201 million (24% YoY growth); Margin: 25.8%
  • Reported EBITDA (including Noida): INR 3,153 million (23% YoY growth); Margin: 23.8%
  • Profit After Tax (PAT): INR 1,573 million (Compared to INR 1,590 million in Q1 FY26, impacted by a non-recurring exceptional income of INR 196 million in the prior year period)

Operational Metrics:

  • Inpatient Volumes: Increased by 28% YoY
  • Outpatient Volumes: Increased by 34% YoY
  • Operational Bed Capacity: 3,737 beds (72 beds added in the quarter: 51 at Noida, 21 at Lucknow)
  • Network Occupancy: 63%
  • ARPOB (Average Revenue Per Occupied Bed): INR 70,244 (5% YoY growth)
  • ARPP (Average Revenue Per Patient): INR 201,891 (introduced as a new metric)
  • International Patient Revenue: INR 782 million (23% YoY growth)
  • OPD Pharmacy Revenue: INR 609 million (51% YoY growth)

Cluster Performance (Re-branded):

  • Cluster 1 (Gurugram, Indore, Ranchi): Revenue: INR 7,715 million (10% YoY growth); EBITDA: INR 1,858 million (13% YoY growth); Margin: 24.1%; Occupancy: 63%; ARPP: INR 219,623
  • Cluster 2 (Lucknow, Patna, Noida): Revenue: INR 4,983 million (55% YoY growth); EBITDA: INR 1,272 million (35% YoY growth); Occupancy: 62%; ARPP: INR 182,407
  • Ex-Noida: Revenue growth 28% YoY; EBITDA growth 40% YoY; Margin: 32%

Medanta Noida Update:

  • Q1 FY27 Performance: Total Income of INR 855 million (up from INR 525 million in Q4 FY26). EBITDA loss reduced sharply to INR 49 million from INR 236 million in Q4 FY26.
  • Outlook: The facility is ramping up faster than expected, and management expects it to achieve EBITDA breakeven earlier than previous expectations. Current occupancy is estimated in the 30-40% range.

Expansion Projects & Capex:

  • Guwahati Project: The plan has been revised and expanded to a 650-bed super specialty hospital (from 400 beds) due to changes in building bylaws and the National Building Code 2026. The estimated project cost is approximately INR 9,700 million.
  • Announced Pipeline: The company's expansion pipeline represents nearly 3,350 additional beds.
  • Q1 Capex: INR 1,610 million was incurred during the quarter.

Additional Notes Section

  • Attachments: The regulatory filing intimates that the transcript of the earnings call was enclosed with the submission to the exchanges.
  • Financial Data: This document itself is a transcript and does not contain new financial data; it is a verbal discussion of results that were previously published. All figures discussed were from the announced results.
  • Compliance: The document is a disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.